|
|
|
| Analysis on Clinical Efficacy and Safety of Mirtazapine in treatment of Patients with Perimenopausal Sleep Disorders |
| SUN Ruitan, PIAO Xiangyu, CAI Ming, et al |
| Zhongshan Hospital Affiliated to Dalian University, Liaoning Dalian 116001, China |
|
|
|
|
Abstract Objective: To study the clinical efficacy of mirtazapine in the treatment of patients with sleep disorders in perimenopausal period. Methods:129 cases of perimenopausal syndrome with sleep disorder were selected and divided into control group (n = 64 cases) and research group (n = 65 cases) according to random number table method. Patients in the control group were treated with oral oryzanol tablets. Patients in the study group were treated with mirtazapine tablets. The PSQI score, the HAMD-17 score, the clinical efficacy of sleep and the clinical effect of depression were compared between the two groups before treatment, 4 weeks after treatment, and 8 weeks after treatment. The EEG results and adverse drug reactions before treatment, 4 weeks after treatment and 8 weeks after treatment were compared. Results:There was no significant difference in PSQI scores between the two groups before treatment (P>0.05). After treatment, the PSQI scores at 4 weeks and 8 weeks were significantly lower in the two groups than before treatment. The scores of the study group were significantly lower than the control group. In the group (P<0.05). The total effective rate of sleep efficacy in the control group was lower than in the study group (χ2=14.291, P<0.05). There was no significant difference in HAMD-17 scores between the two groups before treatment (P>0.05). After treatment, HAMD-17 scores at 4 weeks and 8 weeks were significantly lower in the two groups than before treatment. The scores of the study group were Lower than the control group (P<0.05). The total effective rate of depression in the control group was lower than in the study group (χ2=12.621, P<0.05). There was no significant difference in EEG before treatment between the two groups (P>0.05). There was no significant difference between the two groups after 4 weeks of treatment (P>0.05). After 8 weeks of treatment, the study group was significantly better than the control group (P<0.05). The incidence of adverse reactions in the study group was higher than that in the control group (χ2=4.737, P<0.05). Conclusion:In the treatment of perimenopausal syndrome patients with sleep disorders, mirtazapine has a rapid onset, can improve sleep, and has a significant effect. It has little effect on EEG and has some adverse reactions, but it is necessary to continue to increase the medication time to observe further.
|
|
|
|
|
|
[1] Berling I ,Isbister GK .Mirtazapine overdose is unlikely to cause major toxicity[J].Clin Toxicol:Phila,2014,52(1):20.
[2] 欧秋明,邓思灵.米氮平联合草酸艾司西酞普兰片治疗抑郁症的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(13):1252~1254.
[3] 张云才.米氮平与马普替林治疗广泛性焦虑症的临床效果及不良反应比较分析[J].现代诊断与治疗,2015,26(11):2470~2471.
[4] 李进,段海水,盛久灵,等.米氮平联合rTMS治疗伴睡眠障碍的廖碾焦虑症疗效观察[J].中国实用神经疾病杂志,2016,19(21):12~14.
[5] 王国民,周波,王梅,等.脑电生物反馈疗法联合米氮平治疗抑郁症的临床研究[J].中国基层医药,2017,24(8):1121~1126.
[6] 武玉萍.探讨米氮平与帕罗西汀治疗抑郁症伴睡眠障碍的疗效[J].中国现代药物应用,2017,11(19):95~96.
[7] 蒋国卿,孙晓峰,张文静,等.镇静安神汤联合米氮平片治疗焦虑抑郁状态伴顽固性失眠的临床研究[J].河北中医,2016,38(2):181~184. |
|
|
|
2018, Vol. 24 
